CRISM Therapeutics (LON:CRTX) Posts Earnings Results

CRISM Therapeutics (LON:CRTX) posted its quarterly earnings results on Friday. The company reported GBX (0.05) EPS for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Stock Down 5.0%

LON:CRTX traded down GBX 0.50 on Friday, reaching GBX 9.50. 258,541 shares of the company’s stock were exchanged, compared to its average volume of 291,726. The firm has a market capitalization of £5.15 million, a price-to-earnings ratio of -2.16 and a beta of 0.58. CRISM Therapeutics has a 52-week low of GBX 8 and a 52-week high of GBX 23. The business has a fifty day moving average of GBX 11.50 and a 200-day moving average of GBX 11.67.

CRISM Therapeutics Company Profile

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.